報價延遲最少15分鐘:2024/10/31 18:32 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
10.28 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-3.57/-2.08
|
|
企業價值
490.03M
|
| 資產負債 |
|
每股賬面淨值
4.00
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
0.09
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/10/31 18:32 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program. |